

Antiviral Therapeutics

Technologies, Companies & Markets

By

Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

November 2017

A Jain PharmaBiotech Report

A U T H O R ' S B I O G R A P H Y

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and USA, has held academic positions in several countries and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently he is the CEO and a consultant at Jain PharmaBiotech. Prof. Jain's 473 publications include 28 books (5 as editor + 23 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals. His "Textbook of Gene Therapy" was translated into Chinese in 2000. Recent books include a Handbook of Nanomedicine (2008, Chinese edition published by Peking University Press in 2011, 3rd ed by Springer in 2017), Textbook of Personalized Medicine (2009; Japanese ed 2012; 2nd ed Springer 2015), Handbook of Biomarkers (2010; Chinese edition, Chemical Industry Press 2016, 2nd ed 2017), "Applications of Biotechnology in Cardiovascular Therapeutics" (2011), "Applications of Biotechnology in Neurology (2013)", and "Applications of Biotechnology in Oncology (2014)", all of which have been published by Springer.

**November 2017 (originally published in 2007 and continuously updated since then)
Copyright © 2017 by**

**Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland**

**Tel & Fax: +4161-6924461
Email: info@pharmabiotech.ch
Web site: http://pharmabiotech.ch/**

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

TABLE OF CONTENTS

0. Executive Summary	18
1. Introduction to Virology	20
Introduction.....	20
Evolution of viruses	20
Virus databases	20
A practical classification of viruses	20
The human virome	22
Viral genomics	22
Pathomechanism of viral diseases relevant to therapy	22
Intrinsic host defense against retroviruses	23
Interferon-induced B cell deletion in chronic viral infections	24
Drosha as an interferon-independent antiviral factor	24
Life cycle of virus as basis for antiviral approaches	24
Genetic switch in virus infections	25
Emerging viruses	26
Viral-induced cancer	27
Viral encephalitis	27
Brain's response to viral infections	28
Combination of antivirals with immunosuppression in viral encephalitis	28
Molecular diagnosis of viral diseases	29
Prophylaxis versus therapy.....	29
Economic impact of viral diseases.....	30
Historical landmarks in the development of antiviral therapies	30
2. Antiviral Approaches.....	32
Classification	32
Antiviral drug discovery and development	32
Antiviral drug targets – viral versus cellular	32
Antivirals based on double-stranded RNA activated caspase oligomerizer	34
Antimicrobial peptides	34
Human DDX3 protein as a target for developing broad spectrum antiviral agents	34
Immunological approaches	35
Basics of immune regulation in relation to viruses	35
<i>Effect of viruses on the immune system.....</i>	35
<i>Latent viral infections and the immune system</i>	36
Immunomodulating agents.....	36
<i>Amplification of innate immunity</i>	36
<i>Blocking the effects of thromboxane A2 on thromboxane receptor.....</i>	37
<i>Enhancers of immune system</i>	37
<i>Promoting immune-mediated clearance of a chronic viral infections.....</i>	37
<i>Immunoglobulins</i>	38
<i>Bovine lactoferrin.....</i>	38
<i>Quercetin</i>	39
Monoclonal antibodies	39
<i>Antibody production technologies.....</i>	40
<i>Bavituximab</i>	40
<i>Treatment of viral infection with radiolabeled MAbs</i>	40
<i>Limitations of MAbs and measures to overcome these</i>	41
Interferon-based approaches.....	41
Cholesterol-25-hydroxylase	42
Novel antiviral approaches	42
Phosphatidylethanolamine inhibitors as potential antivirals	42
Squalamine	42
Synthetic modified hypericin compounds.....	43
Targeting Toll-like receptors	43
<i>Potential and drawbacks of TLR-ligands in viral diseases</i>	44
Inhibition of viral transport from cytoplasm into the cell nucleus.....	44
Nitric Oxide based antiviral therapeutics	44
Amino acid cognate anticodon binding specificity.....	45
Antisense approaches to viral infections.....	45
Antisense oligonucleotides	45
Limitations of antisense oligonucleotides as antivirals	46
Phosphorodiamidate morpholino oligomers.....	47
Gene therapy for viral infections.....	47
RNAi.....	47
RNAi screens of viral genomes	48

RNAi for treatment of viral infections	48
Promise and pitfalls of RNAi gene therapy	49
Role of proteomics in virology	49
Interaction of proteins with viruses	50
Quantitative temporal viromics	50
Management of rapidly evolving pathogens	50
Personalized medicine and viral diseases	51
An integrated approach to viral diseases	51
Current problems and needs in antiviral therapy	51
Immunoinformatic approach to vaccine design for emerging infections	52
3. Vaccines for Virus Infections	54
Introduction.....	54
Types of vaccines.....	55
DNA vaccines	55
Live attenuated virus vaccines	56
mRNA vaccines	56
Nanotechnology-based vaccines.....	57
<i>Nanobead adjuvants.....</i>	<i>57</i>
Recombinant viral vaccines	57
SMART vaccines.....	58
Synthetic peptides as vaccines.....	58
Virally vectored vaccines.....	59
Virosomes.....	60
Vaccines based on reverse genetics.....	60
Virus-like particles	60
Routine vaccination in children against viral infections	61
Personalized vaccines	62
Limitations of vaccines	62
Neurological complications of vaccination	62
Expert opinion on antiviral vaccines	63
4. Role of Nanotechnology in Developing Antiviral Agents.....	64
Introduction.....	64
Study of interaction of nanoparticles with viruses.....	64
Exosomes and viral infections.....	65
Nanoparticle antiviral agents.....	65
Silver nanoparticles.....	65
Fullerenes	65
Nanoparticles mimic RNAi for treatment of viral infections.....	66
Nanoviricides	66
Role of micelles in nanopharmaceuticals	66
Some physicochemical characteristics common to polymeric micelles	67
Structure and function of nanoviricides	67
<i>Mechanism of action of NanoViricides</i>	<i>67</i>
<i>Advantages of NanoViricides.....</i>	<i>69</i>
5. Delivery of Antivirals	72
Introduction.....	72
Methods of delivery of antiviral agents	72
Local application of antivirals.....	72
Systemic delivery of of protein-polymer antiviral drugs.....	73
Controlled delivery of antivirals.....	73
Targeted delivery of antivirals	73
Delivery of antivirals to the brain across the blood-brain barrier.....	74
Antiviral vaccine delivery systems	74
Minicell vaccine delivery.....	74
Transnasal delivery of vaccines by Newcastle disease virus as vector	74
Transdermal delivery of vaccines	75
<i>Dissolvable microneedle array for vaccine delivery</i>	<i>75</i>
<i>Electroporation for administering DNA vaccines.....</i>	<i>75</i>
<i>HIV/AIDS vaccination by transdermal application</i>	<i>77</i>
<i>Microneedles for transdermal delivery of vaccines</i>	<i>77</i>
<i>Needle-free delivery of vaccines.....</i>	<i>77</i>
<i>Transdermal vaccines for influenza.....</i>	<i>78</i>
Use of nanotechnology for improving delivery of antivirals	79
Macrophage-based nanoformulated antiretroviral therapy	80
Improvement of antiviral vaccine delivery by nanotechnology.....	80
<i>Bacterial spores for delivery of vaccines.....</i>	<i>80</i>
<i>Chitosan-derived nanoparticles for vaccine delivery.....</i>	<i>80</i>
<i>Dendrimer-based intracellular delivery of antibodies.....</i>	<i>81</i>

<i>Gold nanorods for delivery of RNA immune activator molecules</i>	81
<i>Lipid nanoparticles for immunostimulatory RNA delivery</i>	81
<i>Liposomal antiviral vaccine preparations</i>	82
<i>Nanoparticles for DNA vaccines</i>	82
<i>Nanospheres for controlled release of viral antigens</i>	82
<i>Proteosomes™ as vaccine delivery vehicles</i>	83
<i>Polymeric micellae for delivery of DNA vaccine</i>	83
<i>"Smart" nanoparticles for delivery of vaccines</i>	83
Nanocoating for local viricidal effect	83
Delivery of gene-based antiviral drugs	84
Limitations of delivery of gene, RNAi and antisense therapies	84
Systemic delivery of NanoViricides	85
Concluding remarks on delivery of antiviral agents	85
6. Competitive Assessment of Antiviral Approaches	86
Introduction	86
An ideal antiviral agent	86
SWOT analysis	86
Concluding remarks	89
7. Influenza Viruses	90
Introduction	90
Clinical features of influenza	90
Colds due to rhinovirus	90
Effects of influenza on the respiratory system	91
Effect of avian influenza on the nervous system.....	91
Epidemiology	91
Supermap of avian influenza	91
Influenza A	92
Avian influenza affecting humans.....	92
<i>Human infection with a H7N9 Virus</i>	93
Human influenza versus avian influenza.....	93
H1N1 influenza	94
Immune system and influenza	95
Immune Epitope Database and Analysis Resources	96
Role of Tpl2 in antiviral host defense mechanisms.....	96
Anti-influenza approaches	97
Pharmaceuticals.....	97
Neuraminidase inhibitors.....	97
<i>Mechanism of action</i>	97
<i>Tamiflu</i>	98
<i>Zanamivir</i>	98
<i>CS-8958</i>	98
<i>Peramivir</i>	99
<i>Resistance to neuraminidase inhibitors</i>	100
<i>Adverse effects of neuraminidase inhibitors</i>	100
<i>Concluding remarks on neuraminidase inhibitors</i>	101
Other drugs for influenza	101
<i>Adamantanes</i>	101
<i>Probenecid</i>	102
Current recommendations for the use of antiviral agents for influenza	102
Vaccines	102
<i>Seasonal influenza vaccines</i>	102
<i>Live attenuated influenza vaccine vs. inactivated vaccine</i>	103
<i>Recombinant influenza vaccine</i>	104
<i>Vaccines for H1N1 influenza</i>	104
<i>Vaccines for H7N9 influenza</i>	105
Current status of influenza vaccines	105
<i>Current recommendations for influenza vaccination</i>	105
<i>Current status of vaccine preparedness against seasonal influenza</i>	106
<i>Current status of vaccine preparedness against H5N1</i>	106
Limitations, needs and challenges of influenza vaccines	107
<i>Limitations of current influenza vaccines</i>	107
<i>Needs of influenza vaccines</i>	107
<i>Problems with demand and supply of influenza vaccines</i>	108
<i>Problems with access to virus samples</i>	109
<i>FluVac project for development of pandemic influenza vaccine</i>	109
<i>Influenza vaccines for multiple strains of influenza</i>	109
<i>Quadrivalent influenza vaccine</i>	110
<i>Universal influenza vaccines</i>	110
<i>Future of influenza vaccines</i>	111

Application of new technologies for influenza vaccines	111
<i>Adjuvants</i>	112
<i>Cell culture-derived influenza vaccines</i>	113
<i>DNA vaccines for avian influenza</i>	114
<i>Epitope-based vaccines for influenza</i>	114
<i>Gene-based vaccines for influenza</i>	115
<i>Live attenuated vaccines</i>	115
<i>MABs for passive immunization against avian influenza</i>	115
<i>M2e-based human influenza A vaccine</i>	115
<i>RNA vaccines against influenza A</i>	116
<i>Pre-pandemic split antigen H5N1 vaccine</i>	116
<i>Recombinant-protein based influenza vaccines</i>	117
<i>Synthetic avian influenza vaccine</i>	118
<i>Viral vectors for influenza vaccination</i>	118
<i>Virus-like particles as influenza vaccines</i>	118
RNAi-based approaches	120
<i>Inhibition of influenza virus by siRNAs</i>	120
<i>Limitations of RNAi approach to influenza</i>	121
<i>Challenges and future prospects of siRNAs for influenza</i>	121
Antisense approaches	121
<i>NEUGENE® antisense for inhibition of multiple strains of influenza A</i>	122
Nanoviricides against influenza	122
Other innovative approaches	123
<i>Abatacept</i>	123
<i>Polymeric coatings to inactivate influenza virus</i>	123
<i>Cytotoxic therapy</i>	124
<i>Cyanovirin</i>	124
<i>Fludase</i>	124
<i>Multiferon®</i>	124
<i>Pyrrolidine dithiocarbamate</i>	125
<i>Value of antivirals in preventing spread of influenza after exposure</i>	125
<i>Resistance to influenza therapy and efforts to overcome it</i>	126
FLUCURE project.....	126
NIAID Centers of Excellence for research on pandemic influenza viruses	126
Research on influenza viruses at Bayer	127
Concluding remarks and future	127

8. AIDS/HIV 130

Introduction	130
Epidemiology	130
Current concepts of pathomechanisms	130
Decoding the structure of an entire HIV genome	131
Genetic basis of resistance against HIV	131
Host-pathogen interactions that regulate HIV-1 replication.....	131
Pathogenesis of AIDS	132
Visualization of the interaction of HIV-1 proteins with target cells	133
Viral latency in HIV	133
Complications of AIDS	134
AIDS and the nervous system	134
AIDS wasting syndrome.....	134
Coexistent HIV-1 and HSV-2	135
Coexistent hepatitis virus infections with HIV.....	135
<i>HIV and HBV</i>	135
<i>HIV and HCV</i>	135
Opportunistic infections in AIDS.....	136
<i>HIV and tuberculosis</i>	137
Current therapies	137
Aim of anti-HIV drugs.....	138
Nucleoside reverse transcriptase inhibitors	139
Non-nucleoside reverse transcriptase inhibitors	140
<i>Efavirenz</i>	140
<i>Etravirine</i>	140
Protease inhibitors	140
<i>Tipranavir</i>	140
<i>Darunavir</i>	140
Fusion inhibitors	141
<i>Enfuvirtide</i>	141
Impact of antiretroviral treatment on transmission of HIV	141
Preexposure prophylaxis against HIV	142
Postexposure prophylaxis against HIV	143
Antiretroviral therapy in early asymptomatic HIV infection	143

Limitations of current therapies.....	143
Adverse effects of antiretroviral therapy	144
Drug resistance in AIDS	145
Effect of interruption of HIV treatment.....	145
Reservoirs of HIV Infection.....	146
Persistence of low-level viremia in HIV-1 patients on retroviral therapy	146
Reconsideration of abandoned therapies for AIDS.....	146
Therapies in development.....	146
Drugs in development for HIV/AIDS	146
<i>NRTIs in development</i>	147
<i>NNRIs in development</i>	148
Novel protease inhibitors	148
<i>Overcoming HIV-1 resistance to PIs</i>	148
<i>PPL-100</i>	149
Entry inhibitors targeting CCR5 receptor	149
<i>Maraviroc</i>	150
<i>SP-01A</i>	150
<i>MABs targeting CCR5 receptor</i>	151
<i>PRO 140</i>	151
<i>Ibalizumab</i>	152
Integrase inhibitors	152
<i>Raltegravir (Isentress)</i>	152
<i>Elvitegravir</i>	153
<i>Dolutegravir</i>	153
<i>S/GSK1265744</i>	154
<i>LEDGINS</i>	154
Design of fusion inhibitor peptides against enfuvirtide-resistant HIV-1	154
Maturation inhibitors	155
Blocking of pre-integration complex translocation	155
Immune enhancers	155
Pyrimidinediones.....	156
Combinations of drugs for AIDS	157
<i>Truvada</i>	157
<i>Raltegravir, enfuvirtide, and darunavir</i>	157
Other innovative antiviral approaches against HIV/AIDS	157
A filtration device for HIV-1 as an adjunct to the immune system	157
Anti-HIV therapies based on editing enzymes	157
Anti-HIV activity of drugs that stimulate cholesterol efflux	158
Antiviral hyperactivation-limiting therapeutics	158
ATR kinase as a target for anti-HIV drug discovery.....	158
Blocking of HIV budding by DC-SIGN protein.....	158
Drugs from natural sources	159
Enhancing immune response by blockade of PD-1 receptor	159
IL-2 as adjunct to antiretroviral therapy.....	160
In vitro evaluation of antiviral drug activity	160
Methods for sustaining antiviral activity	160
Microbicidal agents for local application in HIV/AIDS.....	161
<i>Investigational microbicides against HIV and their limitations</i>	161
<i>CCR5 receptor blockers</i>	162
<i>PSC-Rantes and recombinant chemokine analogs</i>	162
<i>HIV-1 entry inhibitor griffithsin as a topical microbicide</i>	163
<i>Nanotechnology-based topical microbicides</i>	163
<i>Next generation microbicides for HIV</i>	163
<i>Vaginal application of anti-retroviral drugs against HIV</i>	163
Nanoviricides for HIV/AIDS	164
Prophylactic measures to prevent HIV infection	164
Selective targeting of ITK to block multiple steps of HIV replication	165
Cell therapy for HIV/AIDS	165
hESCs converted to T-cells for treatment of HIV infection.....	165
Transplantation of genetically modified hematopoietic cells	166
Transplantation of genetically modified T cells	166
Overlapping Peptide-pulsed Autologous Cells.....	166
Gene therapy strategies in HIV/AIDS	167
Gene editing for HIV-1.....	167
Inhibition of HIV-1 replication by lentiviral vectors	168
VRX496-T (Lexgenleucel-T).....	168
Insertion of protective genes into target cells	169
Use of genes to chemosensitize HIV-1 infected cells	169
Autocrine interferon- β production by somatic cell gene therapy.....	169
Intracellular immunization in HIV	169
<i>Engineered cellular proteins such as soluble CD4s</i>	169

<i>Intracellular antibodies</i>	170
<i>Selection of T-cell vaccine antigens</i>	170
<i>Glycoprotein 120 as target for neutralizing HIV-1 antibodies</i>	170
<i>Anti-rev single chain antibody fragment</i>	170
HIV/AIDS vaccines	171
<i>Cell-based vaccines for HIV</i>	171
<i>Delivery of HIV vaccine by an adenoviral vector</i>	172
<i>DNA vaccines for HIV/AIDS</i>	173
<i>Epitope-based DNA vaccines against HIV</i>	174
<i>Gene transfer for HIV vaccination</i>	174
<i>Recombinant HIV proteins</i>	174
<i>Vaccination after discontinuation of antiretroviral treatment</i>	174
Innovations in HIV/AIDS vaccine.....	175
<i>Attenuated rabies virus-based vaccine for HIV</i>	175
<i>Dendritic cell-based vaccine for HIV</i>	175
<i>DermaVir</i>	176
<i>Early control of HIV by an effector memory T cell vaccine</i>	176
<i>Immunogens for inducing broadly neutralizing antibodies</i>	176
<i>MVA nef vaccine</i>	177
<i>Peptide-based vaccine for HIV</i>	177
<i>Personalized vaccine for HIV</i>	177
<i>RV144 HIV vaccine trial</i>	178
<i>Transdermal nanoparticles for immune enhancement in HIV</i>	178
<i>Vaccine to prevent HIV entry at the mucosal level</i>	178
Limitations and future of HIV vaccines	179
Antisense approaches to AIDS	180
<i>Antisense oligodeoxynucleotides</i>	180
<i>Antisense efforts with PNA constructs</i>	180
<i>RNA decoys</i>	181
<i>Ribozymes</i>	181
RNAi applications in HIV/AIDS	182
<i>A multiple shRNA approach for silencing of HIV-1</i>	182
<i>Aptamer-mediated delivery of anti-HIV siRNAs</i>	182
<i>Bispecific siRNA constructs</i>	183
<i>Role of the nef gene during HIV-1 infection and RNAi</i>	183
<i>siRNA-directed inhibition of HIV-1 infection</i>	183
<i>Synergistic effect of snRNA and siRNA</i>	185
<i>Targeting CXCR4 with siRNAs</i>	185
<i>Targeting CCR5 with siRNAs</i>	185
<i>Concluding remarks on RNAi approach to HIV/AIDS</i>	186
Companies involved in developing gene therapy for HIV/AIDS	186
Conclusions regarding gene therapy of HIV/AIDS	187
Testing for new anti-HIV therapies	187
Personalized approach to management of HIV	188
Differences in response of the body to HIV	188
Variations in action of drugs on HIV	188
<i>Drug-resistance in HIV</i>	189
<i>PhenoSense® to test HIV drug resistance</i>	189
<i>Role of biomarkers in management of HIV/AIDS</i>	189
<i>Role of diagnostic testing in management of HIV</i>	190
<i>Prevention of adverse reactions to antiviral drugs</i>	190
<i>Nanoviricides as a personalized approach to HIV</i>	191
Concluding remarks and future prospects	191
9. Hepatitis Viruses	194
Introduction	194
Hepatitis delta virus infection	194
Hepatitis A virus infection	194
Hepatitis E virus infection	195
Epidemiology	195
Structure of the HEV	195
Treatment of HEV infection.....	195
<i>Ribavirin</i>	195
<i>HEV vaccines</i>	196
Epidemiology of HBV	196
Pathogenesis of HBV-induced liver disease	196
Current approaches to management of HBV	197
Entecavir	198
Adefovir dipivoxil	198
Telbivudine	198
Pegylated interferon-alpha	199

Limitations of current therapies and needs of HBV	199
Personalized management of HBV	199
Innovations in the management of HBV	200
Tenofovir disoproxil fumarate	200
Hepatitis B immune globulins	200
<i>Nabi-HB</i>	200
<i>HepaGam B</i>	201
Hepatitis B vaccine composed in a novel nanoemulsion adjuvant	201
Innovative pharmaceuticals for HBV	201
<i>AGX-1009</i>	201
<i>Clevudine</i>	202
<i>Helioxanthin analog 8-1</i>	202
<i>HepDirect prodrugs</i>	202
Monoclonal antibodies for HBV	202
RNAi-based therapy of HBV	203
Personalized treatment of hepatitis B	203
Concluding remarks and future prospects of management of hepatitis B	204
Epidemiology of HCV	204
HCV characteristics	204
Pathomechanism of HCV infection	205
Mechanism of HCV entry	205
HCV and the immune system	205
Mechanism of HCV replication and response to interferon	205
Current approaches to management of HCV	206
Interferon therapy for HCV	206
Limitations of current HCV therapies	206
Novel approaches to HCV	207
HCV protease inhibitors	208
<i>ABT-450</i>	208
<i>Boceprevir</i>	208
<i>Combined daclatasvir and asunaprevir</i>	208
<i>Faldaprevir</i>	209
<i>Narlaprevir</i>	209
<i>Sofosbuvir</i>	209
<i>Simeprevir</i>	209
<i>Small molecule HCV protease inhibitors</i>	210
<i>Telaprevir</i>	210
Innovations in interferon therapy for HCV	211
<i>AlbIFN-α2b</i>	211
<i>Directed evolution of gene-shuffled IFN-α for treatment of HCV</i>	211
<i>GEA007.1</i>	211
<i>Omega DUROS</i>	211
<i>PEG-IFN-λ</i>	212
<i>Personalizing interferon therapy of HCV</i>	212
Innovative ribavirin-based treatments	213
<i>Targeted delivery of hemoglobin-ribavirin conjugate for HCV</i>	213
<i>Taribavirin</i>	213
Nucleoside polymerase inhibitor	213
<i>Deleobuvir</i>	213
<i>Valopicitabine</i>	214
Host cell targets for hepatitis C therapy	214
<i>SP-10</i>	214
NS5a inhibitors	215
<i>Ledipasvir</i>	215
NS5b inhibitors	215
Novel combination of a protease inhibitor and a NS5a inhibitor	215
<i>Zepatier™</i>	215
Compounds targeting HCV receptor E2	216
Cyclophilin inhibitors	216
<i>Alisporivir</i>	216
Methylene blue	217
Naringenin	217
Nitazoxanide	217
Cyclosporine and analogs as anti-HCV agents	218
Clemizole and HCV	219
RNAi-based approaches to HCV	219
<i>Use of adenoviral vectors for RNAi</i>	219
<i>siRNAs for HCV</i>	219
<i>Limitations and drawbacks of siRNA therapy for HCV</i>	220
<i>Role of miRNA in viral infections</i>	221
<i>miR-122 antagonists</i>	221

Gene therapy for HCV.....	221
Vaccines for HCV	222
<i>HCV vaccine based on viral vectors to boost T cell memory</i>	222
<i>Vaccine based on neutralizing antibodies to HCV</i>	222
Clinical trials of HCV therapeutics.....	222
Limitations to the development of effective anti-HCV therapeutics.....	223
<i>Causes of treatment failure in chronic hepatitis C</i>	223
<i>HCV drug resistance</i>	224
Personalized management of HCV infection.....	224
Role of sequencing in personalized management of HCV	225
Concluding remarks about HCV therapy.....	226
Drug combinations for HCV	226
IFN-free combinations for HCV.....	226
Search for new drugs for HCV.....	227
Future needs in HCV therapy	227
10. Miscellaneous Commercially Important Virus Infections	230
Introduction.....	230
Herpes viruses	230
Neuroinvasive herpesviruses	230
Herpes simplex virus	230
Treatment of HSV-1	230
<i>Acyclovir</i>	230
<i>Vaccines for HSV</i>	231
<i>Antisense therapy for HSV-1</i>	231
Herpes simplex virus 2 and genital herpes	232
<i>Famciclovir</i>	232
<i>Pritelivir</i>	232
<i>Intravaginal microbicidal agents for HSV-2</i>	232
<i>Vaccines for HSV-2</i>	233
Herpes simplex keratitis.....	233
Herpes simplex encephalitis	234
Limitations of current HSV therapies.....	234
<i>Genomic diversity of HSV-1 as a cause of failure of vaccines</i>	234
Herpes zoster virus	235
<i>Herpes zoster and chicken pox</i>	235
<i>Epidemiology of herpes zoster</i>	235
<i>Treatment of herpes zoster</i>	235
<i>Herpes zoster vaccines</i>	236
Epstein-Barr virus	237
Latent herpes virus infection	237
Cytomegalovirus	237
Current treatment of CMV	238
<i>Brincidofovir (CMX001)</i>	238
<i>Valganciclovir hydrochloride</i>	238
<i>Limitations of current treatment and future prospects</i>	238
Letermovir	238
T cell therapy for CMV	239
Vaccines for CMV	239
Gene therapy of CMV.....	240
Antisense approach to CMV	240
siRNA treatment of CMV.....	241
Human papilloma virus	241
Epidemiology.....	241
Vaccines for HPV	241
<i>Gardasil</i>	242
<i>Cervarix</i>	242
<i>DNA vaccine VGX-3100</i>	242
<i>GTL001 and GTL002</i>	243
<i>Vaccine based on fusion proteins of HPV envelope</i>	243
<i>Limitations of HPV vaccines</i>	243
Antivirals for HPV	244
<i>Imiquimod</i>	244
Novel approaches against HPV	244
<i>Intrabody strategies for the treatment of HPV</i>	244
<i>A novel peptide to inhibit HPV</i>	245
<i>Heat shock protein-based antivirals</i>	245
Respiratory syncytial virus.....	246
Epidemiology.....	246
Current management of RSV	246
<i>Palivizumab</i>	246

MDT-637.....	246
GS-5806.....	247
RNAi approach to RSV.....	247
Other approaches to RSV antivirals.....	248
Vaccines for RSV.....	248
BCG as a vaccine against RSV.....	248
Oral DNA vaccine for RSV.....	248
Neutralizing antibodies against preactive form of hRSV_F protein.....	248
Challenges for development of RSV antivirals.....	249
Other respiratory viruses.....	249
Parainfluenzavirus type 3.....	249
Human metapneumovirus.....	249
Gastrointestinal viruses.....	250
Noroviruses.....	250
Potential for development of antiviral agents against noroviruses.....	250
Vaccines against noroviruses.....	251
Concluding remarks.....	251
11. Viruses with High Impact but Low Commercial Significance.....	252
Introduction.....	252
Chikungunya fever.....	252
Chikungunya antiviral therapy.....	253
Chikungunya vaccines.....	253
Enteroviruses.....	253
Enterovirus 71.....	253
Coxsackie virus.....	254
Japanese encephalitis.....	254
Vaccines for JE.....	254
Parvovirus.....	255
Polyomavirus JC.....	255
Rabies.....	256
Rabies vaccines.....	256
Recombinant viral vaccines for rabies.....	257
DNA vaccine against rabies.....	257
Rabies immune globulin.....	257
Monoclonal antibodies for rabies.....	257
NanoViricides approach for rabies.....	258
Protein-protein interactions as targets for antirabies drug discovery.....	258
siRNA-based approach against rabies.....	258
The Milwaukee protocol for rabies.....	259
Rotavirus.....	259
Epidemiology.....	259
Rotavirus genome.....	259
Vaccines against rotavirus.....	260
Viral hemorrhagic fevers.....	261
Bas-Congo virus associated with acute hemorrhagic fever.....	262
Crimean-Congo hemorrhagic fever.....	262
Dengue.....	263
Epidemiology.....	263
Antivirals in development.....	264
Dengue vaccines.....	265
Elimination of dengue vector mosquitoes by fungus.....	267
Genetic elimination of dengue vector mosquitoes.....	267
Ebola virus.....	267
Pathogenesis and diagnosis of Ebola virus.....	268
Sequencing of the Ebola genome.....	268
Antiviral approaches to Ebola virus infection.....	269
Antivirals for Ebola based on inhibition of RNA polymerase.....	270
Cell entry blockers as antivirals for filoviruses.....	270
Development of RNAi-based antiviral drugs for Ebola.....	271
EbolaCide.....	271
Monoclonal antibody immunotherapy for Ebola.....	271
Vaccines for Ebola.....	272
Ebola whole virus vaccine.....	274
Companies developing antivirals against Ebola.....	275
Concluding remarks and future.....	275
Human hanta viruses.....	276
Lassa fever.....	276
Marburg hemorrhagic fever.....	277
Therapies in development against Marburg virus.....	277
Yellow fever.....	278

<i>Vaccines for yellow fever</i>	278
<i>Sequencing of Aedes aegypti genome and control of yellow fever</i>	278
West Nile virus	279
Epidemiology.....	279
Pathogenesis.....	279
Treatment of West Nile neuroinvasive disease.....	280
Vaccines against WNV.....	280
Innovative treatments for WNV.....	280
Zika virus	281
Introduction to Zika virus.....	281
ZIKV in the USA.....	281
Clinical features of ZIKV.....	282
Molecular epidemiology of ZIKV.....	282
Molecular diagnosis of ZIKV infection.....	282
Neurological complications of ZIKV infection.....	282
<i>Microcephaly</i>	283
<i>Guillain-Barré syndrome</i>	283
Prevention and treatment of ZIKV infection.....	284
<i>Antiviral agents against ZIKV</i>	284
<i>Preventive measures against ZIKV infection</i>	284
<i>Vaccines for ZIKV</i>	285
<i>WHO views on challenges in management of ZIKV</i>	286
Western equine encephalitis	287
Tick-borne encephalitis	287
TBE vaccines.....	288
Human coronaviruses	288
SARS.....	288
<i>Therapeutic approaches to SARS</i>	289
<i>MABs for SARS</i>	289
<i>siRNA treatment of SARS</i>	290
Middle East respiratory syndrome coronavirus.....	290
<i>Development of therapeutics for MERS-CoV</i>	292
<i>MERS vaccines</i>	292
<i>Future directions for management of MERS</i>	293
Measles	293
Zoonotic viral infections	294
Vaccines for zoonotic viral diseases.....	294
Virus bioterrorism and biowarfare	294
Small pox as a biological weapon.....	295
<i>Status of small pox vaccination</i>	295
Strategies against virus bioterrorism and biowarfare.....	296
<i>Increasing resistance by stimulating innate immune mechanisms</i>	296
<i>Nanoviricides for combating viral bioterrorism</i>	296
Concluding remarks	297
12. Markets for Antivirals	298
Introduction	298
Markets according to disease	298
Influenza market.....	298
HIV/AIDS market.....	299
Hepatitis B and C markets.....	300
<i>Economics of care of hepatitis C and impact on the market</i>	300
Markets for diseases with low commercial significance.....	300
Markets according to products and approaches	301
Market values of monoclonal antibodies for viral diseases	301
Market values of vaccines for viral diseases	301
Markets for vaccines against HPV.....	302
Research investment and potential markets for HIV/AIDS vaccines.....	302
Markets for other antiviral vaccines.....	302
Markets according to geographical areas	302
Emerging markets for antiviral therapeutics.....	303
Geographical distribution of HIV/AIDS market.....	304
Unmet needs in antivirals	304
Policies regarding conquered viral diseases	305
Future of polio vaccine.....	305
Policies concerning HPV vaccine for prevention of cervical cancer	306
<i>HPV vaccine in developing countries</i>	306
Future prospects of innovative approaches	307
US Government support of antiviral efforts.....	308
<i>US Government support for R & D in avian influenza vaccines</i>	308
<i>US Government support for developing anti-bioterrorism agents</i>	308

The European Union support of antiviral research.....	309
<i>European Commission's research support for anti-HIV/AIDS programs</i>	309
<i>European Commission's support anti-influenza programs</i>	310
Collaboration of biotechnology companies with big pharma	311
Strategies for marketing	311
13. Companies	312
Introduction	312
Top companies	312
Profiles of pharmaceutical companies	313
Profiles of biopharmaceutical companies with antiviral products	329
Profiles of antiviral drug companies	416
Profiles of viral vaccine companies	445
Collaborations	525
14. References	532

Tables

Table 1-1: A practical classification of viruses	21
Table 1-2: Viruses causing encephalitis	28
Table 1-3: Vaccines vs therapeutics for viral diseases.....	29
Table 1-4: Historical landmarks in the development of antiviral therapies	30
Table 2-1: Classification of antiviral strategies	32
Table 2-2: Viral vs cellular targets for discovery of antivirals	33
Table 2-3: Viruses amenable to antisense oligonucleotides.....	46
Table 2-4: Inhibition of viral replication by RNAi	48
Table 3-1: Types of vaccines for viral diseases	55
Table 4-1: Role of nanobiotechnology in virology	64
Table 5-1: Methods of delivery of antiviral agents	72
Table 5-2: Role of nanotechnology for improving delivery of antivirals.....	79
Table 5-3: Commercially available liposomal antiviral vaccines	82
Table 6-1: SWOT of monoclonal antibodies	86
Table 6-2: SWOT of agents that prevention viral entry into cells	87
Table 6-3: SWOT of drugs interfering with intracellular replication	87
Table 6-4: SWOT of protease inhibitors	87
Table 6-5: SWOT of integrase inhibitors.....	87
Table 6-6: SWOT of maturation inhibitors	87
Table 6-7: SWOT of neuraminidase inhibitors	88
Table 6-8: SWOT of targeting Toll-like receptors (TLRs).....	88
Table 6-9: SWOT of topical antivirals agents against viral infections	88
Table 6-10: SWOT of gene therapy, antisense oligonucleotides, RNAi	88
Table 6-11: SWOT of vaccines	88
Table 6-12: SWOT of NanoViricides	89
Table 7-1: Anti-influenza approaches	97
Table 7-2: Antiviral drugs used for influenza	97
Table 7-3: Various approaches to production of influenza vaccines.....	112
Table 8-1: Drugs in clinical development for HIV/AIDS	147
Table 8-2: Strategies for gene therapy of AIDS	167
Table 8-3: Classification of HIV/AIDS vaccines in clinical trials.....	171
Table 8-4: Companies involved in developing gene therapy for HIV/AIDS	186
Table 9-1: Innovations in the treatment of HBV	200
Table 9-2: Innovations for management of HCV	207
Table 9-3: Antiviral agents for HCV targeting host cells	214
Table 9-4: HCV drugs in clinical trials	223
Table 10-1: Methods of delivery of acyclovir.....	231
Table 11-1: Antiviral strategies against Ebola virus infection	269
Table 11-2: Companies developing antiviral products against Ebola	275
Table 11-3: ZIKA vaccines in development.....	286
Table 11-4: Strategies against virus bioterrorism and biowarfare.....	296
Table 12-1: Worldwide market for all antiviral approaches 2016-2026.....	298
Table 12-2: Markets for antiviral drugs according to virus infections 2016-2026	298
Table 12-3: Markets values of all drugs for HIV/AIDS 2016-2026.....	299
Table 12-4: Market values of monoclonal antibodies for viral diseases 2016-2026.....	301
Table 12-5: Market values of vaccines for viral diseases 2016-2026	301
Table 12-6: Markets for antiviral drugs according to geographical areas 2016-2026	303
Table 12-7: Markets for antiviral vaccines according to geographical areas 2016-2026	303

Table 12-8: Emerging markets for antiviral drugs according to countries 2016-2026	303
Table 12-9: Emerging markets for antiviral vaccines according to countries 2016-2026	304
Table 13-1: Top antiviral companies.....	312
Table 13-2: Roche antiviral products in development	319
Table 13-3: Collaborations of antiviral companies	525

Figures

Figure 1-1: Varieties of host and cell responses to viral infections	23
Figure 1-2: Cycle of infection and replication of a retrovirus	25
Figure 1-3: Viral-induced cancer	27
Figure 2-1: An integrated approach to viral diseases	51
Figure 4-1: Schematic representation of NanoViricide attacking a virus particle	68
Figure 7-1: Evolution of mutations associated with virulence/drug resistance in H5N1	94
Figure 7-2: Mechanism of development of resistance to oseltamivir	100
Figure 8-1: Mode of action of some current anti-HIV drugs	138
Figure 8-2: Nanocarrier-mediated siRNA delivery for treatment of HIV/AIDS	185
Figure 9-1: Steps of HBV replication and site of action of various drugs	197
Figure 9-2: Omega DUROS device for interferon delivery in chronic hepatitis C.....	212
Figure 11-1: Ebola virus	268
Figure 11-2: Strategies for development of ZIKV vaccines	285
Figure 11-3: Transmission and pathogenesis of MERS-CoV.....	291
Figure 12-1: Unmet needs in antivirals	305